CagriSema Clinical Trials Evidence CagriSema's evidence base is unusually strong for a peptide research stack: two large Phase 3 trials with NEJM publications, plus Phase 1b/2 supporting data
While clinical trials have demonstrated impressive weight loss outcomes, those results were achieved in environments where patients received significant behavioral support alongside the medication
How Hims is making GLP1 weight loss more accessible for men Hims offers access to several weight loss treatment options, which may be available depending on your individual health background and needs
The peptide now sits in a regulatory gray zone not restricted, not approved, waiting for a formal PCAC vote
Ferretta A, Maida I, Guida S, Azzariti A, Porcelli L, Tommasi S, et al